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In its native form, the chemokine 
CX3CL1 is a firmly adhesive molecule 
promoting leukocyte adhesion and 
migration and hence involved, with its 
unique receptor CX3CR1, in various 
inflammatory processes. We investigated 
here the role of molecular aggregation in 
the CX3CL1 adhesiveness. Assays of 
bioluminescence resonance energy transfer 
(BRET) and homogeneous time-resolved 
fluorescence (HTRF) in transfected cell 
lines and in primary cells showed specific 
signals indicative of CX3CL1 clustering. 
Truncation experiments showed that the 
transmembrane domain (TM) played a 
central role in this aggregation. A chimera 
with mutations of the 12 central TM 
residues had significantly reduced BRET 
signals and characteristics of a non-
clustering molecule. This mutant was 
weakly adhesive, according to flow and 
dual pipette adhesion assays and was less 
glycosylated than CX3CL1, although, as we 
demonstrated, loss of glycosylation did not 
affect the CX3CL1 adhesive potency. We 
postulate that cell surfaces express 
CX3CL1 as a constitutive oligomer and 
that this oligomerization is essential for its 
adhesive potency. Inhibition of CX3CL1 
self-assembly could limit the recruitment of 
CX3CR1 positive cells and may be a new 
pathway for anti-inflammatory therapies. 
Migration of circulating leukocytes to 
injury sites is the first step of the inflammation 
process, which involves a sequence of 
coordinated interactions between leukocytes 
and endothelial cells (1). Central to this 
physiological and pathological event are 
chemokines, a family of low molecular weight 
soluble proteins that function to attract 
leukocytes bearing the appropriate receptors 
(2). Chemokines trigger leukocyte activation 
and their firm adhesion to inflamed 
endothelium, mainly through the mediation of 
integrins and their cognate ligands (3). 
Among chemokines, two are exceptions: 
CXCL16 and CX3CL1, are type-I 
membranous proteins: in addition to their 
chemokine domain (called CD), they are 
composed of a long mucin-like stalk, a 
transmembrane domain and a cytoplasmic tail 
(4,5) (Figure 1). The CX3CL1 molecule, with 
its unique CX3CR1 receptor (6), has been 
shown to be central in defenses against 
neurodegenerative disorders (7,8) and against 
several cancers in murine models (9,10). The 
CX3CL1/CX3CR1 axis is also involved in 
various inflammatory diseases (2), including 
renal inflammation (11) and atherosclerosis 
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(12,13). Understanding the structure of this 
pair of molecules is necessary for exploring 
pharmacological methods to regulate their 
activity. The structure of CX3CR1, a receptor 
of the GPCR family, is relatively well known, 
but that of CX3CL1 much less so.  
The CX3CL1-CD (76 residues) - a globular 
protein domain 3 nm in diameter (14) 
maintained by two disulfide bridges - is 
structurally similar to other chemokines. It is 
composed of a disordered N-terminus up to 
the first cysteine (Cys8), a long loop followed 
by a 3-stranded antiparallel β-sheet (residues 
24-51) and a C-terminal α-helix (residues 56-
67) packed against the β-sheet (15). The stalk 
(241 residues) is 26 nm in length (14) and 
highly glycosylated with 17 degenerate 
mucin-like repeats (6,16). This native form 
can be cleaved by various metalloproteinases 
(17,18) to release the soluble form, which, like 
other chemokines, is chemoattractant. In 
contrast, membrane-associated CX3CL1, with 
CX3CR1, mediates stable adhesion of 
leukocytes such as integrins (16,19). The 
mechanism of this adhesive property is poorly 
understood. While we know that the potent 
adhesiveness of CX3CR1 under flow requires 
that CX3CL1-CD have a high affinity for it 
(19), nothing is known about the ligand’s 
quaternary structure. 
Most of the soluble chemokines bind 
sulphated glycoaminoglycans of the 
extracellular matrix and endothelial cell 
surfaces. This immobilization leads to 
chemokine clustering and is essential for 
establishing the chemokine gradient that leads 
to directed migration. Moreover, numerous 
chemokines tend to self-associate at high 
concentration in solution and this clustering 
sometimes appears to be essential to their in 
vivo activity (20). For CX3CL1, however, the 
CD itself remains monomeric in solution, even 
at high concentration (15). The CD structure 
has been studied in crystals (21), where it 
includes four monomers, arranged as two 
asymmetric dimers. The potential aggregation 
of the complete CX3CL1 molecule has not yet 
been investigated, however. We reasoned that 
CX3CL1 clustering could be important for its 
adhesive properties, as it is for integrins (22). 
Among the many methods for studying 
aggregation of cellular proteins, resonance 
energy transfer techniques have emerged as 
useful tools for analyzing the proximity of 
membrane molecules in living cells (23). We 
used these techniques here to study the 
aggregation status of CX3CL1 in its native 
membranous state. We report that CX3CL1 is 
indeed clustered and that this clustering takes 
place primarily through its transmembrane 
domain. Moreover, we show that this 
aggregation is associated with the mature 
glycosylation of the protein and, most 
importantly, is required for its adhesive 
potency in flow conditions (flow adhesion 
assay) and under normal pulling (dual pipette 
assay). 
EXPERIMENTAL PROCEDURES 
Chemicals, proteins and monoclonals- 
Benzyl-2-acetamido-2-deoxy-α-D-galacto-
pyranoside was purchased from Calbiochem 
(VWR International, Fontenay-sous-Bois, 
France), O-sialoglycoprotein endopeptidase 
from Cedarlane Laboratories (Tebu-Bio, Le 
Perray en Yvelines, France). Neuraminidase 
(acylneuraminyl hydrolase) and O-glycosidase 
(endo-D-galactosyl-N-acetyl-α-galactosamino 
hydrolase) came from Roche Diagnostics 
(Meylan France). Monoclonal antibodies 
against CX3CL1-CD (clone 51637) and full-
length CX3CL1 tagged with His6 were 
purchased from R&D Systems (Lille, France), 
and CX3CL1-CD from Peprotech (Levallois-
Perret, France). 
Plasmid constructs- The CX3CL1 
constructs in pcDNA3 (Invitrogen, Cergy-
Pontoise, France), in pEYFP-N1 (Clontech, 
Ozyme, St Quentin-en-Yvelines, France) and 
pRluc-N2 (BioSignal Packard, PerkinElmer, 
Courtaboeuf, France) were made with 
CX3CL1-pBLAST (Invivogen Cayla, 
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Toulouse, France) as template and primers 
containing a Hind III restriction site in 
5’position and a BamH I restriction site in 
3’position for the PCR amplification, as 
explained in Supplementary Table S1. The 
HindIII/BamHI fragment was then cloned in 
the different plasmids. The truncated and 
mutated constructs were generated with the 
QuikChange II Site-Directed Mutagenesis Kit 
according to the manufacturer’s instructions 
(Stratagene, Amsterdam, Netherlands). 
Briefly, 10 ng of various plasmid 
constructions was used as a template, with 
mutated nucleotide primers as described in 
Supplementary Table S1. PCR conditions 
were as follows: pre-denaturing at 95°C for 
3 min, followed by 18 cycles of denaturing at 
95°C for 1 min, annealing at 60°C for 50 s and 
extension at 68°C for 7 min. After digestion 
with DpnI, 2 µl of PCR product was used to 
transform the XL10-Gold Ultracompetent 
cells provided with the kit. Appropriate clones 
were identified by sequencing. 
Cell culture- HEK293 cells were 
maintained in Dulbecco modified Eagle’s 
medium (DMEM) plus GlutaMax I 
(Invitrogen, Cergy-Pontoise, France) 
supplemented with 10% foetal bovine serum, 
and 1 mM sodium pyruvate. To obtain HEK 
clones expressing CX3CL1 or ALA12, 
CX3CL1-pEYFP and ALA12-pEYFP 
constructs were transfected into HEK cells 
with the cationic polymer transfection reagent, 
jetPEI (Polyplus transfection, Ozyme, St 
Quentin-en-Yvelines, France). Stable 
transformant resistant to 0.5 mg/ml G418 
(Invitrogen, Cergy Pontoise, France) was 
selected with a FACS Aria cell sorter (Becton 
Dickinson, Le Pont de Claix, France). 
HUVEC were cultured in endothelial cell 
medium (PAA Laboratories, Les Mureaux, 
France), supplemented with 10% fetal bovine 
serum. HUVEC were incubated for 20 hours 
with TNF-α at 20 ng/ml and interferon γ at 
500 U/ml (Peprotech; Levallois-Perret, 
France) to induce CX3CL1 expression. 
Expression of CX3CL1 on HUVEC and HEK 
cells and clones was tested with 
phycoerythrin-labelled murine anti-CX3CL1 
mAb (mAb clone 51637, R&D Systems Lille, 
France) and analysed by flow cytometry with 
a FACScan (Becton Dickinson, Le Pont-de-
Claix, France). 
BRET- Cells were seeded at a density of 
100 000 cells per well in 12-well dishes 24 h 
before transfection. Transient transfections 
were performed with the cationic polymer 
transfection reagent, JetPEI (Polyplus 
transfection, Ozyme, St Quentin-en-Yvelines, 
France) in NaCl 150mM. In most 
experiments, 0.2 µg of various CX3CL1-
pRluc constructs was transfected alone or with 
increasing quantities of various CX3CL1-
pEYFP constructs. The total amount of DNA 
transfected in each well was completed to 2.2 
µg with empty pcDNA3 vector. After 
overnight incubation, the transfected cells 
were detached with phosphate buffer saline 
(PBS) and washed with HBSS buffer 
supplemented with 10 mM Hepes, 1 mM 
CaCl2 and 0.5 mM MgCl2. They were then 
seeded in 96-well black plates (Packard 
Bioscience, PerkinElmer) in 100 µl 
supplemented HBSS. Coelenterazine H 
(Interchim, Montluçon, France) was added to 
reach a final concentration of 5µM. Readings 
were collected with a microplate analyzer 
(Fusion Packard Bioscience PerkinElmer) that 
allowed the sequential integration of signals 
detected in the 485 ± 20 nm window for 
luciferase and the 540 ± 20 nm window for 
YFP light emissions. The BRET signal was 
determined by calculating the ratio of the light 
intensity emitted by the CX3CL1-YFP over 
the light intensity emitted by the CX3CL1-
Luc. The values were corrected by subtracting 
the background BRET signal detected when 
the CX3CL1-Luc construct was expressed 
alone. The values are the mean over 15 
measurements. To relate the BRET 
measurements to the actual CX3CL1 
concentration, we measured the luminescence 
3
or fluorescence of HEK transfected either with 
CX3CL1-Luc or CX3CL1-YFP constructs and 
quantified their CX3CL1 content in western 
blot experiments with CX3CL1-His6-Tag 
(R&D Systems, Lille, France) as standards 
(Figure 2B). 
HTRF- The monoclonal anti-CX3CR1 
(clone 51637) was labeled with the different 
fluorescent donors or acceptors as described 
previously (24,25). The donor was a pyridine–
bipyridine (PBP) europium cryptate 
(europium cryptate-PBP). The number of 
europium cryptate-PBP per antibody (molar 
ratio) was determined spectrophotometrically 
by measuring their absorbance at 280 nm and 
317 nm and inserting these values into the 
equation 
Molar ratio = (OD317 nm/ εeuropium cryptate-PBP)/-
[(OD280 nm-(OD317 nm/A))/εantibody] 
where the molar extinction coefficient of 
the europium cryptate-PBP (εeuropium cryptate-PBP) 
was taken as 19,800 M−1 cm−1 and that of the 
antibodies as 210,000 M−1 cm−1. The factor A 
expressed the ratio (OD317 nm/OD280 nm) for 
europium cryptate-PBP and was determined to 
be 2. The final molar ratio was determined to 
be 1.1. 
The anti-CX3CR1 monoclonal was labeled 
with the NHS ester derivatives D2 acceptor as 
previously described (26). The final number of 
dyes per antibody was determined 
spectrophotometrically. By using the 
maximum absorption for D2 at 650 nm and its 
molar extinction coefficient value 
(240,000 M−1 cm−1), the final ratio was 
determined to be 1.3. HEK clone cells and 
HUVEC (activated or not) were harvested and 
resuspended in KREBS buffer (Tris/HCL 20 
mM pH 7.4, NaCl 118 mM, glucose 5.6 mM, 
KH2PO4, MgSO4 1.2 mM, KCl 4.7 mM, 
CaCl2 1.8 mM, and BSA 0.1%). Fifty 
thousand cells in 100 µl were distributed in 
96-well black plates (Packard Bioscience, 
PerkinElmer) where 4 nM europium cryptate-
labeled donor anti-CX3CL1 and 4 nM D2-
labelled acceptor antibody (anti-CX3CL1 or 
anti-Flag as control) were already present, 
diluted in the same buffer. After incubation at 
37°C for 4 h, fluorescence emissions were 
measured, at both 620 nm and 665 nm, on a 
multidetection microplate reader (PHERAstar, 
BMG Labtech). 
The HTRF ratio was calculated as R= 
(fluorescence at 665 nm/fluorescence at 
620 nm)x104. The specific signal over 
background, noted as Delta F (∆F), was 
calculated with the following formula: 
∆F= (Rpos-Rneg)/Rneg 
where Rpos corresponds to the ratio with 
anti-CX3CL1 mAb as the acceptor and Rneg to 
the ratio with anti-Flag mAb as the acceptor. 
Static adhesion assay- Two different assays 
were performed. In the cell-cell model, 
performed as previously described (27), CHO-
CX3CR1 and parental CHO were grown in 
supplemented DMEM in 96-well plate (5.104 
cells per well) and washed in HBSS buffer. 
Then 105 HEK cells expressing variants of 
CX3CL1 were added for 45 min at room 
temperature. In the cell to protein adhesion 
model, a monoclonal anti-polyhistidine 
antibody (MAB050, R&D Systems, Lille, 
France) (250 ng in 25 mM Tris, pH 8, 150 
mM NaCl) was adsorbed for 2 h at room 
temperature to flat-bottom 96-well microtiter 
plates (Nunc A/S, Roskilde, Denmark). Then 
CX3CL1-H6, diluted in the same buffer, was 
incubated overnight at 4°C at a concentration 
of 1.8 µg/ml (50 µl/well in triplicate). 
Adhesion of HEK-CX3CR1 cells was 
performed as previously described (27) with 
an incubation time of 45 min at room 
temperature in HBSS buffer with or without 
enzymatic treatment.  
In both cases, before the adhesion assay, 
the cells were labeled with 1 mM 
5(6)carboxyfluorescein diacetate, 
succinimidyl ester (Interchim, Montluçon, 
France) and the microplate was read at 535 
nm with a microplate analyzer (Fusion 
Packard Bioscience PerkinElmer). 
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Deglycosylation treatment- The adsorbed 
protein was digested with 4 mU 
neuraminidase in 40 mM Tris pH8 and 4 mM 
CaCl2 for 2 h at 37°C before incubation with 1 
mU O-glycosidase in PBS for 4 h at 37°C. 
Western blotting using an anti-CX3CL1 
antibody analyzed the digested protein. 
Parallel Plate Laminar Flow Chamber 
Adhesion Assay- The technique we used has 
previously been thoroughly described (28 ). 
Briefly, the coverslips were cultured with 
adherent clone HEK cells expressing either 
CX3CL1 or ALA12 mutant. The coverslip 
was mounted in a chamber set on the stage of 
an inverted microscope (TE300, Nikon, 
France) equipped with a phase contrast 10x 
objective (Nikon, n.a. 0.25) and a cooled CCD 
camera (Sensicam, PCO, Kelheim, Germany). 
The entire apparatus was kept at 37°C by a 
thermostatic chamber (Life Imaging Services, 
Reinach, Switzerland). HEK-CX3CR1 clone 
cells were suspended in PBS, incubated for 30 
min at 37°C with 5 µM carboxy-SNARF-1 
(SemiNAphtoRhodaFluor-1-
acetoxymethylester, Molecular Probes, 
Invitrogen, Cergy-Pontoise, France) for 
labeling and resuspended in flow buffer 
(HBSS supplemented with 2.5 mM EDTA, 
2.5 mM EGTA, 10 mM HEPES and 2 mg/ml 
BSA) at 106 cells per ml. A syringe pump 
(PHD 2000; Harvard Apparatus, Les Ulis, 
France) drove 0.5 ml of cell suspension 
through the chamber at a wall shear stress of 
1.5 dynes.cm-2. After a 10-min wash at 
1.5 dynes.cm-2, fluorescent images of three 
separate 0.5 mm2 fields were recorded to count 
the adherent cells (excitation 450-500 nm, 
emission 510-560 nm, dichroic filter Q505lp, 
Chroma, Brattleboro, VT, USA). The number 
of non-specific adhering cells was obtained in 
the same manner, except that the HEK-
CX3CR1 clone cells were preincubated for 
2 min with 100 nM soluble CX3CL1-CD 
(chemokine domain alone, R&D Systems, 
Lille, France) 
Dual Pipette Aspiration Technique- The 
dual pipette adhesion assay was performed as 
already described (28 ). Briefly, two cells, 
collected by gentle aspiration onto the tip of 
each pipette (cell number 1 in pipette A, cell 2 
in pipette B), were brought into contact with 
the micromanipulators and allowed to remain 
in contact for 4 minutes. To separate the cells, 
aspiration in pipette B was maintained at a 
level sufficiently high to hold cell number 2 
tightly, while the aspiration in pipette A was 
increased in steps measured with a pressure 
sensor (Validyne, model DP103-38; ranging 
from 0 to 50 000 Pa). After each step, the 
pipettes were moved apart in an effort to 
detach the adherent cells from one another. A 
pair pulled intact from pipette A was moved 
back to the pipette orifice, the aspiration in the 
pipette was increased, and another attempt 
was made to detach the cells from each other. 
The cycle was repeated until the level of 
aspiration in pipette A was sufficient to pull 
one cell apart from the other. The aspiration 
employed in each cycle was monitored 
continuously. The values recorded for each of 
the last two cycles in the series (Pn-1 and Pn) 
were used to calculate the separation force F 
for the pair tested, with the equation: 
F = π (d/2)2 (Pn-1+Pn)/2 (1) 
with d the internal diameter of pipette A. The 
results were expressed as the mean ± SEM for 
14 measurements. 
RESULTS 
BRET of CX3CL1 in the HEK cell line- To 
investigate by BRET the aggregation state of 
the chemokine CX3CL1 in its native 
membranous form, we developed various 
constructs of CX3CL1 chimera that expressed 
luciferase (Luc) or yellow fluorescence 
protein (YFP) on the cytoplasmic C-terminal 
side. As expected, the tagged CX3CL1 was 
expressed at the plasma membrane in 
transiently transfected HEK cells (Figure 2A 
insert). The membrane-targeted CX3CL1-YFP 
or CX3CL1-Luc accounted for about 50% of 
the total cellular CX3CL1, as already shown 
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for CX3CL1-GFP chimera (29). Finally, our 
CX3CL1 chimera also functioned as native 
CX3CL1 according to adhesion tests (data not 
shown), as the GFP chimera did (29). 
Using such chimera with a ratio of 1/10 
YFP (acceptor) over Luc (donor), we 
measured a high BRET ratio (Figure 2A 
right), higher than that obtained when the 
CX3CL1-YFP plasmid was replaced by the 
empty pEYFP construct (Figure 2A left), by 
CXCL16-YFP (Figure 2A middle) or by 
ICAM-4-YFP (not shown). These data suggest 
the specificity of the homotypic CX3CL1 
BRET and show for the first time the probable 
self-assembly of CX3CL1 proteins in a 
cellular context. After transfecting HEK cells 
with various amounts of CX3CL1-YFP and a 
constant amount of CX3CL1-Luc (yielding 
1.5 fmole CX3CL1-Luc per mg total protein, 
see Figure 2B), we plotted the BRET data 
versus the CX3CL1-YFP/CX3CL1-Luc ratio 
and observed a saturation curve (Figure 2C, 
filled squares), as expected for specific 
clustering (30,31). In contrast, the same curve 
plotted with CXCL16-YFP replacing 
CX3CL1-YFP remained at low amplitude 
(empty squares). Working with a constant 
CX3CL1-YFP/CX3CL1-Luc ratio, here equal 
to 5 (Figure 2D), we verified that the BRET 
level was constant when plotted against the 
total amount of tagged CX3CL1 (donor plus 
acceptor) (Figure 2D) and against the 
CX3CL1-YFP concentration (acceptor) 
(Figure 2E). Indeed, when BRET is specific, 
its amplitude should not depend on the total 
amount of interacting proteins (30-34) or on 
the concentration of the donor moiety (30). 
Finally, the significant BRET decrease in the 
presence of an excess of an untagged unit 
(Figure 2F) showed that the BRET was 
specific and not due to random collision. We 
concluded that CX3CL1 appears to aggregate 
specifically, at least in the HEK cell line. 
HTRF measurements with cellular 
CX3CL1- To test whether native CX3CL1 
aggregates similarly in primary cells, we used 
the method called homogeneous time-resolved 
fluorescence (HTRF) (35), which has been 
applied to detect biomolecular interactions 
(36), including ligand-enzyme relations (37) 
and protein clustering (24). It consists here of 
measuring the resonance energy transfer 
between labeled antibodies specific against 
CX3CL1. Using both stably CX3CL1-
expressing HEK cells (data not shown) and 
cytokine-activated HUVEC, also expressing 
CX3CL1 (16,38) (Figure 3A), we observed a 
marked level of energy transfer (Figure 3B, 
right, solid bar), substantially higher than the 
level observed with irrelevant monoclonals 
(Figure 3B, right, empty bar). This result was 
confirmed by plotting HTRF signals as the 
difference between specific and non-specific 
data (∆F, see Materials and Methods) (Figure 
3B, insert). In contrast, measurements of 
resting HUVEC, which do not express 
CX3CL1 (Figure 3A), showed no specific 
HTRF (Figure 3B left and insert). 
Accordingly, CX3CL1 appears natively 
aggregated when it is expressed at the external 
membrane of primary cells.  
CX3CL1 clustering is mainly due to its 
transmembrane domain- We next sought to 
identify the domain of CX3CL1 involved in 
clustering, by progressively deleting the 
external - first the CD and then the mucin 
stalk - and intracellular domains of the 
molecule (Figure 4, top). We first checked that 
all these constructs, when transfected in HEK, 
produced proteins that effectively targeted the 
membrane (Figure 4A-C) and were expressed 
at levels similar to that of whole CX3CL1 
(Figure 2A insert). After transfection with 
these constructs, the HEK still exhibited 
BRET. Each construct produced BRET with 
saturation curves (BRET versus [YFP]/[Luc] 
at a constant Luc concentration) (Figure 4D). 
Moreover, the BRET of these truncated 
CX3CL1 constructs met the criteria for 
specificity described above (Figure 2D), even 
the TM alone (Figure 4E). Yet, the Muc and 
TM constructs gave a BRETmax lower than 
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that of CX3CL1 (Figure 2C), while the 
TM&cyto construct gave a higher level 
(Figures 4D and 4E). One should here recall 
that the BRET was not only dependent of the 
proximity of the donor and acceptor moieties, 
but also of their relative orientation (39). 
Hence little conformation change could 
dramatically affect the BRET level. 
Nevertheless, all the constructs we tested gave 
specific BRET (Figures 4D and 4E). So our 
data strongly suggest that the TM domain 
alone still aggregates and that this domain is 
the primary site involved in CX3CL1 
clustering.  
The ALA12 CX3CL1 mutant is not fully 
glycosylated and does not cluster- For 
additional evidence that CX3CL1 clusters 
through its TM, we looked for the TM 
residues whose mutations could suppress the 
specific BRET observed with the entire 
protein. We mutated sequentially in alanine 
the residues thought to be important for self-
association of transmembrane helices (Figure 
5 upper panel), such as glycine (40), leucine 
(41) and phenylalanine (42), and observed no 
significant decrease of BRET (Figure 5 lower 
panel).  
We therefore decided to proceed to larger 
modifications. The 321-325 and 326-332 
residues were replaced by their alanine 
counterparts, for the ALA5 and ALA7 
mutants (Figure 6, upper panel). We also 
mutated the 321-332 residues together, for an 
ALA12 mutant (Figure 6, upper panel). 
Protein expression of ALA5 and ALA7 at the 
membrane was assessed by fluorescence 
imaging (Figures 6A and 6B) and flow 
cytometry (data not shown) and was 
substantial, similar to that of the native 
CX3CL1 (Figure 2A insert). The ALA12 
mutant, however, was mainly intracellular 
(Figure 6C). Flow cytometry assays revealed 
that it was expressed overall at the same level 
as the other mutants (data not shown), but that 
the expression of the ALA12 protein at the 
membrane level was actually half that of that 
of CX3CL1 and of the ALA5 and ALA7 
constructs. 
Moreover, western blot analysis revealed 
that each construct gave rise to two CX3CL1-
YFP species (Figure 6D), one mature and 
complete, with a molecular weight of 120 kDa 
(90 kDa for CX3CL1 plus 30 kDa for YFP) 
and a smaller one (60 kDa plus 30 kDa for 
YFP). The latter did not seem to be a 
truncated fragment of the mature form, since it 
contained both the CD and YFP moieties, as 
assayed by western blot (data not shown). It 
most probably corresponds to the 60-kDa 
form pointed out in an earlier study (17) as an 
immature, intracellular form of CX3CL1. 
Interestingly, this shorter form, which 
accounted for only a small proportion of the 
expression of the ALA5 and ALA7 mutants, 
was the major form in the ALA12 mutant 
(Figure 5D). This is consistent with its 
intracellular location (Figure 5C).  
The ALA5 and ALA7 mutants exhibited 
BRET saturation curves (Figure 6E) similar to 
those of CX3CL1 (Figure 2C). Figure 6F 
shows that the BRET data for the ALA5 and 
ALA7 mutants was characteristic of specific 
BRET (constant versus acceptor plus donor). 
The ALA12 mutant, in contrast, had a very 
low BRET amplitude (Figure 6E), which was 
not constant when plotted against the total 
amount of tagged protein (Figure 6G): the 
BRET data were clearly linear and going to 
near zero, that is, they corresponded to a non-
specific aggregation (30,33). The BRET curve 
versus the acceptor concentration behaved 
similarly (data not shown) and thus confirmed 
that the BRET of ALA12 was mainly 
unspecific. Mutation of the 12 central residues 
of the TM domain of CX3CL1 led to less 
protein maturation (Figure 6D) and, according 
to BRET assays, to reduced ability to 
aggregate (Figures 6E and 6G).  
Role of clustering in the adhesive potency 
of CX3CL1- To test the non-clustering 
CX3CL1 mutant functionally, we derived 
HEK clones that stably expressed either the 
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CX3CL1-YFP or the ALA12-YFP chimera. 
We obtained two clones with similar YFP 
fluorescence and expressing the same level of 
CX3CL1 at the cell membrane, according to 
flow cytometry (Figure 7A) and confocal 
microscopy (Figure 7B). Both clones 
expressed the two forms of CX3CL1 (90 and 
120 kDa, Figure 7B), both of which were full-
length peptides, since they were recognized by 
both anti-CX3CL1-CD (Figure 7C left) and 
anti-YFP (Figure 7C middle). The complete, 
mature form is the major form in the 
CX3CL1-YFP clone, either in the whole cell 
(Figure 7C left) or at the external membrane 
level, as shown by immunoprecipitation of the 
CX3CL1 protein accessible from outside 
(Figure 7C right). Conversely, in confirmation 
of the data obtained with transient 
transfectants (Figure 6D), the smaller form is 
the main component of the ALA12–YFP 
clone (Figure 7C left) and is dominantly 
expressed at the clone’s surface membrane 
(Figure 7C right). Finally, both clones 
released a similar amount of the 80 kDa 
soluble form of CX3CL1 (data not shown), 
probably after cleavage by ADAM10 and 
ADAM17 (17,43-46). 
Both clones were assayed for their 
adhesiveness to a CX3CR1-expressing HEK 
or CHO clone. When assayed in static 
conditions, both clones specifically adhered to 
CX3CR1 positive CHO cells (Figure 7D). 
Despite a similar CX3CL1 surface expression 
(Figure 7A), the number of adhering ALA12-
YFP cells was significantly lower than the 
number of adhering CX3CL1-YFP clone cells. 
Besides, in flow conditions at 1.5 dyne.cm-2, 
the number of CX3CR1-positive HEK clone 
cells adhering to ALA12 cells was less than 
25% of the number adhering to standard 
CX3CL1 cells (Figure 7E). In the dual pipette 
assay, quantifying the strength required to 
dissociate an adhesive cell pair (28), a 
dissociation force of approximately 1 nN 
(Figure 7F) was sufficient to tear apart the 
ALA12-CX3CR1 paired cells. This level was 
also obtained with parental HEK (28) and was 
considered as non specific adhesion. In 
contrast, a dissociation force of 4 nN was 
required for CX3CL1-CX3CR1 pairs. The 
latter value is similar to that already found for 
adhesion of HEK cells expressing CX3CR1 
and CX3CL1 without the YFP extension (28). 
Taken together, our data indicate that the 
primary TM domain of CX3CL1 is required 
for the shear-resistant adhesiveness of the 
CX3CL1/CX3CR1 pair. 
Role of glycosylation in CX3CL1 adhesive 
potency- The preceding data show that the 
ALA12 mutant - mainly containing a non-
clustering and light form of CX3CL1 - was 
hardly adhesive. Moreover, this form was 
lighter, probably because it was not fully 
glycosylated (Figure 7B). To determine 
whether either clustering or glycosylation was 
required for adhesion, our HEK clone that 
expressed CX3CL1-YFP was treated with 
benzyl-2-acetamido-2-deoxy-α-D-galacto-
pyranoside, which inhibits glycosylation of 
the mucin family proteins (47). Alternatively, 
it was incubated with neuraminidase 
(acylneuraminyl hydrolase) plus O-glycosi-
dase (endo-D-galactosyl-N-acetyl-α-galacto-
samino hydrolase), which deglycosylates 
cellular CXCL16 (45). Unfortunately, the 
apparent molecular weight of CX3CL1 was 
not altered by the application of any of these 
treatments to our CX3CL1-YFP clone (either 
on intact cells or on cell lysate). We therefore 
decided to work with the commercially 
available external moiety of the CX3CL1 
molecule, containing the CD domain and most 
of the mucin stalk fused to a His6 tag (48). 
This purified protein had an apparent 
molecular weight of 90 kDa (Figure 8A, lane 
a) and showed adhesive properties under both 
static (Figure 8B, lane a) and flow conditions 
(Figure 8C, lane a). After treatment with 
neuraminidase, the molecular weight of 
CX3CL1-His6 was reduced to 65-70 kDa 
(Figure 8A, lane b). If O-glycosidase was 
included in the treatment, the CX3CL1-His6 
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was found around 60 kDa (Figure 8A, lane c), 
that is equivalent to that of the lighter form of 
CX3CL1 detected in our CX3CL1 and 
ALA12 HEK clones (Figure 7B). However, 
these lighter forms of CX3CL1 displayed the 
same adhesion features than the mature form 
(Figures 8B and 8C, lanes b and c). The 
failure of the deglycosylation treatment to 
affect either static adhesion (Figure 8B) or 
adhesion under flow (Figure 8C) suggests that 
mature glycosylation is not involved in the 
adhesive potency of CX3CR1. 
DISCUSSION 
The CX3CL1/CX3CR1 axis is a highly 
adhesive pair involved in the firm adhesion of 
monocytes or lymphocytes on activated 
endothelium (4). CX3CL1 adhesion potency is 
completely independent of that of selectin or 
integrin (16) but is similar in strength to that 
of integrins (16,19). The adhesive potency of 
integrins relies on molecular activation and 
aggregation, due in part to the fact that the 
molecule is a flexible heterodimer forming 
what have been called “compliant legs” (22). 
In contrast, the relation between the structural 
characteristics of CX3CL1 and its adhesive 
features remains largely unknown. Earlier 
studies showed that the mucin stalk 
contributes to the ligand’s ability to act as an 
adhesion molecule in flow conditions (48) and 
that the nature of the stalk is unimportant, 
since it can be replaced by the rod-like 
segment of E-selectin (14). Nonetheless, the 
potential self-aggregation of CX3CL1 has not 
yet been investigated.  
The BRET method is now widely used as a 
molecular proximity assay to study the 
clustering of membrane proteins including 
circadian clock proteins (49), integrins (50), 
growth factor receptors (51) and GPCR 
(52,53). Working with CX3CL1, we found a 
specific and large BRET level in the HEK cell 
line (Figure 2A) and the CHO cell line (data 
not shown). Several criteria are used to assess 
BRET and ensure that its results are not due 
merely to random protein (bystander) 
interactions, but to constitutive clustering (30-
33,53). BRET of CX3CL1 in the HEK cell 
line met all of them: (i) Replacing one of the 
monomers with an irrelevant protein produced 
no transfer (Figure 2A); (ii) expression of an 
excess of a non-tagged unit along with the 
Luc- and YFP-chimeras reduced BRET 
(Figure 2F); (iii) BRET signals for a given 
acceptor/donor ratio (at constant amount of 
donor) reached saturation: at a sufficient 
acceptor concentration, each donor molecule 
was engaged in a cluster and the BRET signal 
reached a maximum (Figure 2C). If BRET 
were due to random collision, BRET 
amplitude would increase continuously with 
the acceptor/donor ratio; (iv) BRET versus the 
total amount of tagged protein (donor plus 
acceptor) at a given acceptor/donor ratio 
should be constant or vary only slightly: this 
curve should not go to zero at low protein 
density, as recently pointed out (32,33), and it 
clearly did not for CX3CL1 (Figure 2D). The 
same criterion can be checked by directly 
plotting the BRET against the acceptor 
concentrations (30) (Figure 2E). These data, 
obtained with transfected HEK cells were 
supplemented with data from HTRF of 
primary cells (Figure 3B). All the data sets 
provided convergent evidence that CX3CL1 
behaves as an aggregating protein, both as a 
transfected protein in cell lines and as a native 
protein expressed in HUVEC cells. 
Moreover, flow cytometry and 
fluorescence imaging of our transfected HEK 
showed that approximately half of the 
CX3CL1 was located at the membrane (see 
Figure 2A), consistent with recent findings 
(29). The HTRF experiment (Figure 3B) 
showed that the membrane functional 
CX3CL1 molecules were definitely clustered. 
Because the BRET assay did not discriminate 
between intracellular and membranous 
proteins, we cannot assert the aggregation 
status of the intracellular CX3CL1 pool. 
We found that the major content of the 
ALA12 mutant was a 60-kDa protein (90 kDa 
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with the YFP tag), while the ALA5 and ALA7 
mutants were, like the native CX3CL1 (90 
kDa, 120 kDa with the YFP tag, Figures 6D 
and 7C) composed of the mature molecule. 
Our data indicate that the 60-kDa species 
cannot be a shorter fragment of CX3CL1 and 
is thus likely to represent immature, not fully 
glycosylated, species. First, we found that this 
small form exists in cells expressing the native 
CX3CL1 (Figures 6D left and 7B left), as 
previously observed (17,45). It also has the 
same terminals as the native CX3CL1 (Figure 
7B left and centre). Moreover, it is 
preferentially located intracellularly (Figure 
6C), as is the immature form of CX3CL1 (17). 
Finally, enzymatic deglycosylation of the 
purified CX3CL1 gives rise to a 60-kDa form 
(Figure 8A). Hence, our data suggest that the 
same conformational characteristic of the TM 
is essential for CX3CL1 clustering, mature 
glycosylation and targeting the mature form to 
the external membrane. Nonetheless, we 
isolated a HEK clone that expressed an 
immature, non-aggregating CX3CL1 molecule 
that is well inserted in the external membrane 
(ALA12, Figures 7A, 7B and 7C right). 
To identify the domain primarily involved 
in the self-association, we conducted 
numerous mutation experiments (Figures 4, 5 
and 6), which demonstrated the essential role 
of the TM. This was confirmed by our 
observation that the BRET of CX3CL1 was 
completely abolished after treatment with a 
concentration of Triton X100 as low as 0.1% 
(data not shown). We failed however to 
pinpoint the precise sequence motif involved 
in the TM helix association. Self-association 
of transmembrane helices may involve a 
glycine motif, as in glycophorin A (40), or 
leucine zipper (41) or a phenylalanine in a 
“ball and socket” dimer interface (42). Our 
work shows that it is not the glycine or leucine 
or phenylalanine residues alone that are 
involved (Figure 5). In addition, replacement 
of the 321-325 residues (ALA5) left the 
specific BRET unchanged and replacement of 
the 326-332 residues (ALA7) increased it 
(Figure 6). The higher BRET amplitude for 
some mutants, e.g. TM&cyto (Figure 4D) and 
ALA7 (Figure 6E), compared with the whole 
CX3CL1 molecule, is probably due to slight 
modifications of relative orientations of the 
dipole moments of the acceptor and donor, 
which can lead to more efficient BRET (39). 
Indeed, relatively small conformational 
changes could dramatically affect the BRET 
level (54-57), included conformational 
changes due to genetic variations (58) 
Finally, the simultaneous replacement of 12 
TM residues (ALA12) dramatically decreased 
BRET and made it non-specific (Figures 6E 
and 6G). Thus, a long stretch of the TM 
domain appears to be involved in aggregation 
but no special motif has a particular role; other 
examples of this type of structure have already 
been observed (59). One might think that 
CX3CL1 is clustered in some membrane 
microdomains, such as “lipid rafts”, although 
recent work showed that CX3CL1 in renal 
tubular epithelial cells is found outside lipid 
rafts (60). The CX3CL1 aggregation may also 
be due to external constraints imposed by 
companion molecules. However, the 
observation of CX3CL1 aggregation in very 
different cellular contexts, such as HUVEC, 
HEK and CHO cell lines, suggests that it is 
most likely due to intrinsic properties of the 
CX3CL1-TM domain. Since this aggregation 
is functional and takes place in various 
cellular environments, we propose that it 
corresponds to oligomerization. Definitive 
proof of this oligomerization of CX3CL1, 
however, must await reconstitution in 
membrane models, and many questions must 
be answered before we can understand how it 
takes place. How can such small (0.5 nm in 
diameter) TM domains interact despite the 
large diameter of mucin-like glycosylated 
moieties (14)? How many monomers are 
involved in this aggregation/oligomerization? 
The unique adhesive features of CX3CL1 
under flow depend on its CD. They do not 
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change after replacement of the mucin stalk by 
the rod-like segment of E-selectin (14). On the 
other hand, the chimeras that replaced the CD 
of CX3CL1 with those of CCL2, CCL4, 
CCL5, CCL21 or CXCL8 did not act as 
adhesion molecules with the cognate receptors 
(48). The ability of CX3CL1 to mediate 
adhesion may therefore depend on its unique 
slow receptor off-rate. Our data here (Figure 
7) complement these findings in showing that 
self-assembly is also required for the adhesive 
potency of CX3CL1. The ALA12 molecule 
behaves similarly to the CX3CL1 chimera 
presenting CCL2 or CXCL8 as a CD (48): it 
adheres to CX3CR1 in a mild static assay 
(Figure 7D), but is not resistant to shear stress 
(Figures 7E-F). 
Our results with the purified CX3CL1-H6 
external domain (Figure 8) show that 
glycosylation is not involved in adhesive 
potency. The immobilized protein, however, is 
not representative of the complete protein 
embedded in a cell membrane. Unfortunately, 
we could not test that point directly: all of our 
trials to deglycosylate cellular CX3CL1 were 
unsuccessful (see Results). Nonetheless, the 
molecular weight loss of the CX3CL1-H6 
molecule induced by our deglycosylation 
treatment was equivalent to the difference in 
molecular weight between the mature 
CX3CL1 form and the immature form 
(Figures 6 and 7) and there is evidence that the 
major form of the ALA12 mutant is the 
deglycosylated and immature form of 
CX3CL1. These results suggest that, while 
glycosylation has no direct role in the 
adhesive CX3CL1-CX3CR1 interaction, it 
facilitates the emergence of the CX3CL1-CD 
moiety from the glycocalyx layer and 
therefore enables the ligand to target the 
receptor.  
We can conclude that the adhesiveness of 
CX3CL1 requires at least three simultaneous 
conditions: (i) the unique features of the 
CX3CL1-CD, probably related to its slow 
receptor off-rate (48); (ii) presentation of the 
CX3CL1-CD atop a glycosylated stalk (48), 
the nature of which is unimportant (14); and 
(iii) a TM domain capable of aggregation (this 
work). Another chemokine - CXCL16 - has a 
similar primary structure (5), but seems to be 
less adhesive in flow conditions than CX3CL1 
(61) (our un published data). It is therefore 
essential to investigate its structure-function 
relations, to compare its function to that of 
CX3CL1.  
That clustering is crucial for the adhesive 
capacity of CX3CL1 expands its similarity 
with others adhesion molecules. Integrin 
clustering increases its avidity (62) and is 
required for efficient leukocyte adhesion (63). 
Similarly, the dimerization of P-selectin 
glycoprotein ligand-1 (PSGL-1) is required for 
optimal recognition of P-selectin (64). 
Moreover, as shown here for CX3CL1, 
mutational changes in the TM domain of 
PSGL-1 affect its self-assembly (65).  
Our data open up the possibility of 
inhibiting CX3CL1 self-assembly by using 
competing peptides analogous to the TM 
domain, as already done for integrins (66). 
This could lead to the specific inhibition of the 
adhesive function of CX3CL1 and thus help to 
delineate the different roles of the two forms 
of this chemokine. More importantly, it also 
points out a new way to antagonize the 
CX3CL1 function specifically, without 
interfering with the CX3CL1-CX3CR1 
interaction. This type of pharmacology may be 
helpful in treating the ever-growing number of 
diseases in which CX3CL1 is involved (3), 
especially atherogenesis (13), inflammation 
diseases (2) and degenerative disorders (7,8). 
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FIGURE LEGENDS 
Figure 1. Schematic drawing of the structure of the CX3CL1 molecule. The domains of 
CX3CL1 are drawn according to the available structural data (6,14). 
 
Figure 2. Characteristics of BRET of CX3CL1 in HEK cells. A. HEK-293 cells were 
transfected with 0.05 µg CX3CL1-Luc and 0.5 µg of various YFP constructs: empty pEYFP 
(left), CX3CL1-YFP (middle), CXCL16-YFP (right). The values are the mean of 15 
measurements (± SD). Insert. Fluorescence microscopy imaging of HEK cells transfected with 
CX3CL1-YFP (bar = 50 µm). B. HEK cells were transfected with 1, 2 or 3µg of CX3CLI-Luc or 
of CX3CL1-YFP constructs. The luminescence of fluorescence of 50000, 100000 and 200000 
cells was then measured. Besides, the CX3CL1 content of each transfectants was analyzed by 
SDS-PAGE and western blot and evaluated with CX3CL1-H6 as standard. C. BRET variation 
using HEK cells transfected with a constant amount of donor (CX3CL1-Luc) and increasing 
amount of acceptor (CX3CL1-YFP) (■). CX3CL1-Luc and CX3CL1-YFP contents in each 
sample were quantified with the calibration curve in Figure 2B. Here the CX3CL1-Luc was kept 
constant at 1.5 fmole/mg total protein. The same measurements were taken with CXCL16-YFP 
as acceptor (□). The data were fitted with GraphPad Prism4 with one-site binding hyperbola. The 
resulting BRETmax was 0.230 for CX3CL1-Luc/CX3CL1-YFP and 0.027 for CX3CL1-
Luc/CXCL16-YFP. D. BRET variation using HEK cells co-transfected with CX3CL1-Luc and 
CX3CL1-YFP at a constant ratio ([YFP]/[Luc] = 5). The linear regression is given and indicates 
that BRET is constant in this range. E. BRET variation versus CX3CL1-YFP concentration using 
HEK cells transfected with various amounts of CX3CL1-Luc and CX3CL1-YFP. F. HEK-293 
cells were transfected with 0.1 µg CX3CL1-Luc and 0.2 µg CX3CL1-YFP supplemented with 2 
µg of empty pcDNA3 (left) or of CX3CL1-pcDNA3 (right). The values are the mean of 15 
measurements (± SEM). The difference between the CX3CL1 BRET ratio with or without native 
CX3CL1 was significant (***: p<0.0001). The CX3CL1 content of each sample was analyzed by 
western blot to check that the untagged CX3CL1 expression did not change expression of 
CX3CL1-Luc and CX3CL1-YFP (data not shown). 
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Figure 3. HTRF measurements of CX3CL1 in HUVEC. A. Resting HUVEC (dotted line) and 
activated HUVEC (continuous line) were stained with phycoerythrin murine mAb anti-CX3CL1 
and analyzed by flow cytometry. B. Resting HUVEC (left), activated HUVEC (right) were 
stained with anti-CX3CL1 mAb labeled with cryptate (donor) and with D2-labelled anti-
CX3CL1 mAb (acceptor) (filled bars) as described in Methods. Control measurements were 
made with anti-Flag D2-labelled mAb as acceptor (empty bars). The FRET signals were plotted 
as HTRF ratio R (R= (fluorescence at 665 nm/fluorescence at 620nm) x104). The HTRF 
difference between HUVEC and activated HUVEC was significant (*** p<0.0001). Insert. The 
specific signal over background called ∆F was calculated with the following formula: ∆F= (Rpos-
Rneg)/Rneg where Rpos corresponds to the HTRF ratio with anti-CX3CL1 mAb as acceptor and 
Rneg to the ratio with anti-Flag mAb as acceptor. 
 
Figure 4. BRET of CX3CL1 deletion mutants. A, B, C. HEK cells were co-transfected with 
YFP-tagged constructs containing the various truncated CX3CL1-YFP constructs and were 
observed with fluorescence microscopy (bar = 50 µm). D. BRET variation using HEK cells co-
transfected with a constant amount of Luc-tagged truncated CX3CL1 constructs (4, 4 and 7 
fmol/mg total protein for respectively Muc, TM&cyto and TM mutants) and increasing amount 
of YFP-tagged constructs, as indicated. The data were calibrated (Figure 2B) and fitted using 
GraphPad Prism4 with one-site binding hyperbola. E. BRET variation using HEK cells co-
transfected with Rluc- and YFP-tagged constructs containing truncated CX3CL1 at a constant 
[YFP]/[Luc] ratio. Muc (circles, [YFP]/[Luc] = 20). TM&cyto (triangles, [YFP]/[Luc] = 40) and 
TM (diamonds,[YFP]/[Luc] = 12). 
 
Figure 5. BRET of the CX3CL1 mutants with modifications in the TM. HEK cells were co-
transfected with a constant amount of CX3CL1-Luc-tagged constructs and increasing amounts of 
CX3CL1-YFP constructs with various mutations in the TM domain, as indicated in the top of the 
figure. In each case, BRETmax (± SE) was analyzed as done in Figure 2C. 
 
Figure 6. BRET of the CX3CL1 mutants with modifications in the TM. A, B, C. The various 
CX3CL1-YFP constructs were transiently expressed in the HEK cell line and observed with 
fluorescence microscopy (bar = 50 µm). D. Lysates of HEK transiently transfected with the 
various CX3CL1-YFP constructs were analyzed by SDS-PAGE and western blot with a goat 
anti-CX3CL1 antibody. E. HEK cells were co-transfected with a constant amount of Luc-tagged 
constructs (giving 1.5 fmol/mg total protein) and increasing amount of YFP-tagged constructs, as 
indicated. In each case, data were calibrated (Figure 2B) and fitted with GraphPad Prism4 with 
one-site binding hyperbola. F. BRET variation using HEK cells co-transfected with various 
amounts of Luc-tagged constructs and YFP-tagged constructs at a constant ratio (ALA7 
triangles, [YFP]/[Luc] = 5; ALA5 diamonds [YFP]/[Luc] = 9). G. BRET variation using HEK 
cells co-transfected with various amounts of ALA12 Luc-tagged constructs and ALA12 YFP-
tagged constructs at a constant ratio, with [YFP]/[Luc] = 9. 
 
Figure 7. Adhesive properties of HEK clone cells expressing CX3CL1-YFP or ALA12-YFP. 
A. Parental HEK cells (continuous line), stable HEK clone expressing CX3CL1-YFP (fine dotted 
line) or ALA 12-YFP (large dotted line) were stained with phycoerythrin-labeled murine anti-
CX3CL1 mAb and analyzed by flow cytometry. B. The two clones were observed with confocal 
microscopy (Leica SP2 AOBS) (bar = 50µm) C. The two clones were analyzed by SDS-PAGE 
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and western blot using antibodies against CX3CL1 (left) or against YFP (middle). For 
immunoprecipitation of antigen located at the cell surface (right), 2x106 cells of both clones were 
incubated in suspension for 1 h at 4°C with 5 µg of murine mAb anti-human CX3CL1 in PBS 
plus 0,2% BSA. After two washings in cold PBS, the cells were lysed in lysis buffer (150 mM 
NaCl, 50 mM Tris-HCl pH 8, 1% Nonidep P40 (Sigma, Saint Quentin-Fallavier, France), 
Complete (Roche Diagnostics, Meylan, France). The immune complex was separated with 
Protein G-agarose (Sigma, Saint Quentin-Fallavier, France) and analyzed by western blotting, 
with a goat anti-human CX3CL1. D. HEK-CX3CL1 or HEK-ALA12 clone cells (105 cells/well) 
labelled with CFSE were deposited onto confluent CX3CR1-CHO cell or parental CHO cell 
monolayers. At the end of incubation period and after washings, the plate was read at 535nM as 
described in Experimental Procedures. The adherent cells are expressed as percentage of total 
cells minus the mean background corresponding to the number of HEK-CX3CL1 or ALA12 
cells adhering on parental CHO cells. E. HEK clone cells expressing CX3CR1 were suspended 
and assayed for adhesion in a parallel plate laminar flow chamber with coverslips coated with 
adherent HEK-CX3CL1 or HEK-ALA12 clones as described in Methods section. Adhering cells 
were counted after 10 minutes over four fields (mean ± SEM). The unspecifically adhering cell 
numbers were obtained in the same conditions, after addition of 100 nM FKN in HEK-CX3CR1 
cells before injection in the flow chamber. The difference between the number of cells 
specifically adhering either on CX3CL1 or on ALA12 was significant (*** p = 0.002). This 
result was characteristic of three independent experiments. F. HEK-CX3CL1 or HEK-ALA12 
clones were assayed for adhesion by the dual pipette aspiration technique with HEK-CX3CR1 
clone cells as described in Methods section. The dissociation force was evaluated after 4 minutes 
of adhesion (mean over 14 cell pair measurements ± SEM). The difference between adhesion of 
the CX3CL1/CX3CR1 and ALA12/CX3CR1 pairs was significant (*** p = 0.008).  
 
Figure 8. Functional analysis of the deglycosylated CX3CL1. A. 90 ng of CX3CL1-H6 was 
treated or not (a) with neuraminidase alone (b) or with neuraminidase and O-glycosidase (c). 
Then the proteins were analyzed by SDS-PAGE and western blot. B. 90 ng of CX3CL1-H6 was 
absorbed onto wells of flat-bottom 96-well microtiter plates and treated or not (a) with 
neuraminidase alone (b) or with neuraminidase and O-glycosidase (c). Then 105 HEK-CX3CR1 
cells were added and incubated for 45 minutes before washing. The results are expressed as 
percentage of total cells (mean of triplicates ± SD). The control corresponds to a well without 
CX3CL1-H6. C. HEK clone cells expressing CX3CR1 were suspended and assayed for adhesion 
in the presence (filled bars) or absence (empty bars) of 100nM CX3CL1 in a parallel plate 
laminar flow chamber with coverslips coated with 180 ng CX3CL1-H6 treated or not (a) with 
neuraminidase alone (b) or neuraminidase and with O-glycosidase (c). The results are expressed 
as the mean of triplicate experiments (± SEM). The data is representative of three experiments. 
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